MPX Bioceutical Corporation announced consolidated earnings results for the fourth quarter and full year ended March 31, 2018. For the quarter, revenue was CAD 7,980,065 against CAD 4,383,962 a year ago. Adjusted LBITDA was CAD 1,305,169 against CAD 288,430 a year ago. Loss from operations was CAD 5,325,403 against CAD 3,794,613 a year ago. Net loss before taxes was CAD 6,116,861 against CAD 4,475,234 a year ago. Comprehensive Loss was CAD 3,022,202 against CAD 3,554,854 a year ago. Net loss per share basic and diluted was CAD 0.01 against CAD 0.02 a year ago. For the year, revenue was CAD 21,332,640 against CAD 4,383,962 a year ago. Revenue was generated primarily by the Company's Arizona management operations including sales from the three dispensaries in Arizona as well as wholesale sales of and MPX branded concentrates to other licensed dispensaries operating within the State and one month of sales from the recent THC acquisition. Adjusted LBITDA was CAD 2,697,784 against CAD 1,220,365 a year ago. This was the result of additional costs incurred throughout the year, driven by costs largely related to continued capacity expansion. Loss from operations was CAD 9,538,796 against CAD 4,726,548 a year ago. Net loss before taxes was CAD 21,368,076 against CAD 5,648,545 a year ago. Comprehensive loss was CAD 18,806,538 against CAD 4,737,573 a year ago. Net loss per share basic and diluted was CAD 0.07 against CAD 0.06 a year ago.